Polycystic Ovary Syndrome Clinical Trial
Official title:
Randomized, Single Blind, Prospective Clinical Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle.
Verified date | February 2019 |
Source | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Polycystic ovary occurs in 15-20% of the population will be submitted to TRA. Whether it is
associated with other signs or symptoms (polycystic ovarian syndrome) as if presented in
isolation, its therapeutic management has special connotations sometimes favoring the low
response although the standard is the tendency to hyperresponsiveness.
Although there are studies comparing the combination of FSH and LH and FSH in controlled
hyperstimulation of these patients, there are no previous prospective randomized studies
comparing administration of urinary FSH (hFSH-HP) with a combination of FSH and HCG (HMG HP).
Therefore the aim of this study is to prove that both drugs are comparable in the treatment
of these patients. The test substances are marketed in Spain (Fostipur and Meriofert,
respectively) with an indication for use in these patients. In this study both medicines will
be administered in a randomized way under the usual conditions in which it is used in routine
clinical practice to compare the quantity of mature oocytes respect to the total oocytes
obtained, as a primary outcome measure.
Status | Terminated |
Enrollment | 19 |
Est. completion date | May 9, 2018 |
Est. primary completion date | May 9, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 38 Years |
Eligibility |
Inclusion Criteria: - Female age between 18 and 38 years (inclusive) - Women with a BMI under 30 kg / m2 - Diagnosis of polycystic ovary syndrome (according to criteria of Rotterdam) - Women who want pregnancy - Basal basal FSH levels under or equal 10 IU / l - Infertility justify treatment with in vitro fertilization / intracytoplasmic sperm injection - To be included in a protocol with GnRH antagonist - Presence of both ovaries and uterus able to support embryo implantation and pregnancy - Absence of pregnancy before starting ovarian stimulation - Written consent Exclusion Criteria: - Severe male factor not allowing an in vitro fertilization / intracytoplasmic sperm injection with ejaculated sample - Patients with low ovarian reserve - Important endocrine-metabolic systemic diseases affecting pituitary, thyroid, adrenals, pancreas, liver or kidney - HIV seropositivity - To have frozen embryos from previous cycles of assisted reproduction - Undiagnosed vaginal haemorrhage - Poor response in previous cycles of in vitro fertilization with standard stimulation protocols - Pregnancy, lactation or contraindication to get pregnant - Malformations of the sexual organs incompatible with pregnancy - History of allergy to gonadotrophin preparations or its excipients - Alcohol, drugs or psychotropic addiction - Concurrent participation in another study - Previous history of severe hyperstimulation syndrome - Concomitant medication that may interfere with the study medication: different hormonal treatments used in the study, other thyroid hormones, antipsychotics, anxiolytics, hypnotics, sedatives, chronic treatment with inhibitors of prostaglandin |
Country | Name | City | State |
---|---|---|---|
Spain | Fundació Puigvert | Barcelona | |
Spain | Hospital de la Santa Creu i Sant Pau | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Programa de Reproducción Asistida F. Puigvert - HSCSP |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quantity of mature oocytes respect to the total oocytes | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03142633 -
MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
|
||
Completed |
NCT06158932 -
A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04932070 -
Berberine and Polycystic Ovary Syndrome
|
N/A | |
Suspended |
NCT03652987 -
Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
|
||
Completed |
NCT03480022 -
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
|
Phase 3 | |
Active, not recruiting |
NCT03043924 -
Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS)
|
N/A | |
Completed |
NCT05246306 -
Aerobic Capacity and Physical Fitness Level of Adolescents With PCOS
|
||
Completed |
NCT05981742 -
Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS
|
Phase 2 | |
Completed |
NCT05702957 -
Letrozole vs Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovarian Syndrome
|
Phase 2/Phase 3 | |
Completed |
NCT05029492 -
Effect of Visceral Manipulation on PCOS
|
N/A | |
Completed |
NCT02924025 -
Motivational Interviewing as an Intervention for PCOS
|
N/A | |
Not yet recruiting |
NCT02255578 -
Endobarrier Treatment in Women With PCOS
|
Phase 3 | |
Not yet recruiting |
NCT00883259 -
Metformin and Gestational Diabetes in High-risk Patients: a RCTs
|
Phase 4 | |
Completed |
NCT02098668 -
Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON
|
N/A | |
Withdrawn |
NCT01638988 -
Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin
|
Phase 3 | |
Completed |
NCT01462864 -
Development of a Structured Education Programme for Women With Polycystic Ovary Syndrome
|
N/A | |
Recruiting |
NCT01431352 -
Letrozole Versus Chinese Herbal Medicine on Polycystic Ovary Syndrome (PCOS)
|
N/A | |
Completed |
NCT00989781 -
Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome
|
N/A |